Phase II trial of maintenance daily oral thalidomide in patients with extensive-stage small cell lung cancer (ES-SCLC) in remission

Cooney, Matthew M.; Subbiah, Shanmuga; Rm, Chapman; Ness, Anne; Rutherford, Kimberly; Warren, Graham; Saltzman, Joel; Mekhail, Tarek; Levitan, Nathan; Dowlati, Afshin

doi:10.1200/jco.2005.23.16_suppl.7166

Cited by 6 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Initial reports of maintenance therapy with thalidomide following induction with platinum-etoposide in patients with extensive stage SCLC have been promising [48], and this approach needs evaluation in the future. The London Lung Cancer Group is currently conducting a randomized trial evaluating the role of adding thalidomide to a combination of carboplatin and etoposide in patients with both limited-and extensive stage SCLC.…”

Section: Angiogenesismentioning

confidence: 98%

Targeted therapy for small cell lung cancer

Ganti

Panwalkar

2007

Targ Oncol

View full text Add to dashboard Cite

Small cell lung cancer (SCLC) is very aggressive clinically, and current cytotoxic therapy has only a limited impact on survival. The development of targeted therapy for SCLC has lagged behind that of non-small cell lung cancer. Current drugs under investigation include those targeting the angiogenetic, apoptotic, sonic hedgehog, and mammalian target of rapamycin (mTOR) pathways. Vaccines seem to be promising adjunctive therapies. This review will present the available data on these agents. Common genetic abnormalities seen in SCLC, which could serve as potential future targets are also discussed.

show abstract

Section: Angiogenesismentioning

confidence: 98%

Targeted therapy for small cell lung cancer

Ganti

Panwalkar

2007

Targ Oncol

View full text Add to dashboard Cite

show abstract

Angiogenesis Inhibitors in Lung Cancer

Horn

Sandler

2010

Lung Cancer

View full text Add to dashboard Cite

Management of small cell lung cancer

Ciombor

Lima

2006

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Small cell lung cancer (SCLC) is an aggressive type of lung cancer characterized by rapid growth and early metastasis. It is chemosensitive and radiosensitive, yet decades of research investigating multimodality treatments have failed to control or cure this disease in most patients. First-line treatment of limited-stage disease consists of chemotherapy (often etoposide/cisplatin or etoposide/carboplatin) combined with thoracic radiation therapy (TRT), followed by prophylactic cranial irradiation to decrease brain metastases as a site of disease progression for those who experience complete remission or a very good partial response to multimodality treatment. In a Japanese trial, the combination of irinotecan and cisplatin had initially shown promise in treating patients with extensive-stage SCLC, but a confirmatory trial in the United States did not find a difference in overall survival with irinotecan/cisplatin versus etoposide/cisplatin. Adding a third drug to the etoposide/cisplatin combination, as well as other triplet therapies, has mostly been ineffective in improving outcomes. Variables in chemotherapy administration, including maintenance therapy, alternating non-cross-resistance regimens, and dose intensification, have not been shown to increase survival at large. In terms of radiation therapy, early administration of TRT concurrent with chemotherapy, and hyperfractionation, have been beneficial in treatment of limited-stage disease. In patients who relapse, second-line therapy options consist of reinduction of previous chemotherapy or administration of a single agent. Targeted biological therapies for SCLC are now being investigated, and although a great deal of research remains to be done, these agents and their derivatives may provide the most hope for future treatment of SCLC.

show abstract

Phase II trial of maintenance daily oral thalidomide in patients with extensive-stage small cell lung cancer (ES-SCLC) in remission

Cited by 6 publications

References 0 publications

Targeted therapy for small cell lung cancer

Targeted therapy for small cell lung cancer

Angiogenesis Inhibitors in Lung Cancer

Management of small cell lung cancer

Contact Info

Product

Resources

About